<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848692</url>
  </required_header>
  <id_info>
    <org_study_id>18257</org_study_id>
    <secondary_id>EudraCT: 2007-007973-22</secondary_id>
    <nct_id>NCT00848692</nct_id>
  </id_info>
  <brief_title>Drug Intervention in Chronic Fatigue Syndrome</brief_title>
  <acronym>KTS-1-2008</acronym>
  <official_title>B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on pilot patient observations,the investigators anticipate that chronic fatigue
      syndrome (CFS) patients may benefit from B-cell depletion therapy.

      The hypothesis is that at least a subset of CFS patients have an activated immune system
      involving B-lymphocytes, and that B-cell depletion may alleviate symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom alleviation, as compared to baseline, measured by standardized self-reports and quality of life schemes.</measure>
    <time_frame>3 months after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom alleviation, as compared to baseline, measured by standardized self-reports and quality of life schemes</measure>
    <time_frame>2, 4, 6, 8, 10, 12 months after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Fatigue Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline (NaCl 0,9 %) (placebo)</intervention_name>
    <description>Two infusions of saline (NaCl 0,9 %) given two weeks apart</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  verified chronic fatigue syndrome (CDC-criteria)

          -  age &gt;18 and &lt;60 years

          -  informed consent

        Exclusion Criteria:

          -  pregnancy or lactation

          -  previous malignant disease except basal cell carcinoma of skin and cervical carcinoma
             in situ

          -  previous long-term use of immunosuppressive drugs

          -  previous exposure to rituximab

          -  endogenous depression

          -  multi-allergy with risk of serious drug reaction

          -  reduced renal function (creatinin &gt; 1.2 x UNL)

          -  reduced liver function (bilirubin or transaminases &gt; 1.5 x UNL)

          -  known HIV infection

          -  signs of active viral infection by pretreatment investigations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olav Mella, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology and Medical Physics, Haukeland University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology and Medical Physics, Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Olav Mella, Professor, Department Director</name_title>
    <organization>Department of Oncology and Medical Physics, Haukeland University Hospital</organization>
  </responsible_party>
  <keyword>Chronic Fatigue Syndrome</keyword>
  <keyword>CFS</keyword>
  <keyword>Myalgic Encephalomyelitis</keyword>
  <keyword>Rituximab</keyword>
  <keyword>B-lymphocyte depletion</keyword>
  <keyword>B-cell depletion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

